Deregulated expression of HOXB13 in a subset of estrogen receptor-positive breast cancer patients treated with tamoxifen monotherapy is associated with an aggressive clinical course and poor outcome. Because the ovary is another hormone-responsive organ, we investigated whether HOXB13 plays a role in ovarian cancer progression. We show that HOXB13 is expressed in multiple human ovarian cancer cell lines and tumors and that knockdown of endogenous HOXB13 by RNA interference in human ovarian cancer cell lines is associated with reduced cell proliferation. Ectopic expression of HOXB13 is capable of transforming p53 ؊/؊ mouse embryonic fibroblasts and promotes cell proliferation and anchorage-independent growth in mouse ovarian cancer cell lines that contain genetic alterations in p53, myc, and ras. In this genetically defined cell line model of ovarian cancer, we demonstrate that HOXB13 collaborates with activated ras to markedly promote tumor growth in vivo and that HOXB13 confers resistance to tamoxifen-mediated apoptosis. Taken together, our results support a pro-proliferative and pro-survival role for HOXB13 in ovarian cancer.
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estrogen ͉ Ras ͉ tamoxifen ͉ homeobox ͉ mouse model T he HOX family of homeobox genes is an important group of developmental transcriptional regulators that are critical for various aspects of differentiation and morphogenesis (1) . Similar to other genes that regulate normal growth and differentiation, HOX genes have been implicated in different aspects of the oncogenic process, because ectopic expression of HOX genes promotes cellular transformation in vitro and tumorigenesis in vivo (2) . Of particular interest to human tumorigenesis is the observation that various human tumors including breast, colon, prostate, and lung carcinomas display altered HOX gene expression (3) (4) (5) (6) (7) . Several HOX family members have been implicated in ovarian cancer differentiation (8, 9) , although it is unknown whether HOX genes play a direct role in ovarian cancer progression.
We recently demonstrated that dysregulated HOXB13 expression in human breast cancer is directly correlated with poor clinical outcome in estrogen receptor (ER)-positive breast cancer patients treated with tamoxifen monotherapy (10) . In preliminary functional studies, we demonstrated that ectopic expression of HOXB13 in a nontransformed human mammary epithelial cell confers increased cell migration and invasion, two characteristics associated with tumor aggressiveness (10) . Consistent with a possible role in human tumorigenesis, others have recently shown that HOXB13 is overexpressed in human endometrial, ovarian, and cervical carcinomas and that overexpression of HOXB13 is associated with the invasiveness of ovarian and endometrial cancer cells (11) (12) (13) . Collectively, these observations suggest that HOXB13 may play an important role in tumors arising from endocrine-responsive organs. Herein, we characterized the expression of HOXB13 in ovarian cancer cell lines and tumors. Furthermore, we investigated the potential growth modulatory role of HOXB13 in vitro and in a genetically defined mouse model of ovarian cancer.
Results and Discussion

HOXB13 Is Expressed in Multiple Human Ovarian Cancer Cell Lines and
Tumors. We have recently demonstrated in a cohort of 42 sporadic breast cancer patients that HOXB13 is markedly upregulated in Ϸ30% of human breast cancers, whereas little (Ͻ15% of all cases) or no expression (Ͼ85% of all cases) is observed in patient-matched adult normal breast epithelium (10) . To determine the prevalence of HOXB13 gene expression in ovarian cancer, we performed RT-PCR analysis in 10 different human ovarian cell lines and 10 primary ovarian tumors. HOXB13 was expressed in all but one ovarian cancer cell line (Fig. 1A ) and in 5 of 9 ovarian carcinomas that were examined (Fig. 1B) . These findings are consistent with the previous observations that HOXB13 demonstrates high expression in a subset of ovarian cancers (12) with little to no expression in normal ovarian tissue (12, 14) .
Knockdown of Endogenous HOXB13 in Human Ovarian Cancer Cell
Lines Is Associated with Reduced Cell Proliferation. To determine the functional role of endogenous HOXB13, we used an RNAi approach in human ovarian cancer cell lines. To efficiently inhibit endogenous HOXB13, we used lentiviral vectors encoding small hairpin RNA (shRNA) constructs targeting HOXB13. Lentiviral infection resulted in a 50-95% knockdown of endogenous HOXB13 as assessed by real-time quantitative RT-PCR (data not shown). To determine the effect of shRNA on cell growth, we performed colony growth assays and assessed proliferation by measuring light absorbance of cell-associated crystal-violet dye. Compared with a nontarget shRNA control, the HOXB13-directed shRNA lentiviral constructs (shHOXB13-1 and shHOXB13-2) resulted in decreased colony formation in SKOV-3 and OVCAR-5 cell lines (Fig. 1C) . These results support the hypothesis that expression of HOXB13 modulates growth of ovarian cancer cell lines. The observation that HOXB13 is expressed in a high percentage of human ovarian cancer cell lines and tumors, and that the expression of HOXB13 in human breast cancer is associated with a more aggressive clinical course compared with breast tumors that do not express HOXB13, raises the possibility that HOXB13 may play an important role in tumor progression. The possibility that HOXB13 promotes ovarian tumor growth was tested by ectopic expression of this gene by replication-competent avian leukosis virus long terminal repeat with splice acceptor (RCAS) retroviral delivery in T1 ovarian cancer cells, a cell line generated from mouse ovarian surface epithelial cells that contains genetic alterations in p53, c-myc, and K-ras (15) (16) (17) and has undetectable expression of endogenous HOXB13 by RT-PCR analysis ( Fig.  2A ) and Western blotting (Fig. 2B ). These cells display typical epithelial morphology, are sensitive to contact inhibition, and are capable of forming colonies in soft agar. Infection of T1 cells with the RCAS-GFP retrovirus (henceforth designated T1-GFP cells) did not change any of these properties in culture. Ectopic expression of the human HOXB13 in T1 cells resulted in expression of HOXB13 mRNA (Fig. 2 A) and protein ( Fig. 2B) , and, as expected, the human HOXB13 protein exhibited nuclear localization (Fig. 2C ). T1 cells infected with RCAS-HOXB13 (T1-HOXB13 cells) displayed a distinct phenotypic change, characterized by a spindle-like morphology (Fig. 2D) . When grown at high density, the T1-HOXB13 cells displayed a loss of cell contact inhibition that was accompanied by threedimensional growth (piling up of cells), diminished cell cohesion (Fig. 2E) , a reduced rate of apoptosis (Fig. 2G) , and an enhanced rate of proliferation ( Fig. 2H ) with decreased G 1 arrest (Fig. 2I ) compared with T1-GFP cells. Furthermore, in an anchorageindependent growth assay, T1-HOXB13 cells displayed rapid proliferation in soft agar compared with the control T1-GFP cells (Fig. 2F ).
HOXB13 Enhances Tumor Growth. To determine whether HOXB13 can induce cell transformation and tumor progression in vivo, mouse embryonic fibroblasts (MEFs) were infected in vitro with the retroviral constructs RCAS-GFP and RCAS-HOXB13. HOXB13 was unable to transform wild-type MEFs; however, it induced a tumorigenic transformation of MEFs from p53 Ϫ/Ϫ embryos. Tumor development occurred within 45 days in three of seven mice injected with the p53 Ϫ/Ϫ plus RCAS-HOXB13 MEFs and in zero of seven mice injected with the p53 Ϫ/Ϫ plus RCAS-GFP MEFs (Fig. 3A) .
To explore the potential collaborative interaction of HOXB13 with known signaling pathways, we ectopically expressed HOXB13 in mouse ovarian epithelial tumor cell lines that contain various combinations of genetic alterations in p53, c-myc, K-ras, and Akt. We have generated four independent mouse ovarian cancer cell lines: T1 and T11 cells that contain genetic alterations in p53, c-myc, and K-ras, and T2 and T22 cell lines with alterations in p53, c-myc, and Akt (Table 1) . Two independent T1 and T11 cell lines give rise to Ϸ0.5 cm 3 s.c. tumors 3-4 weeks after injection into nude mice, whereas infection of the T1 and T11 cell lines with the control retrovirus (RCAS-GFP) did not alter the rate of tumor growth. However, infection with RCAS-HOXB13 in T1 and T11 cells resulted in extremely rapid tumor growth and formation of large (Ն1.4 cm 3 ) tumors between 9 and 19 days after s.c. injection in 30 of 30 mice ( Fig. 3B and Table 1) . Similarly, i.p. injection of T1ϩRCAS-HOXB13 (T1-HOXB13) cells into nude mice resulted in ascites accumulation and tumor formation in four of four mice in 12 days (Fig. 3C) , whereas the mice injected with T1 cells infected with RCAS-GFP (T1-GFP) did not show any signs of ascites or tumor formation at that time (Fig. 3D) . HOXB13 was more effective in inducing tumor growth in T1 and T11 cells than any other oncogene that we have tested to date, including activated Akt1, Her-2/neu, and middle T-antigen (data not shown). Ectopic expression of HOXB13 without the homeobox domain in T1 cells did not result in enhanced tumor growth (data not shown), implicating DNA binding function in pro-growth activity of HOXB13.
In contrast to T1 and T11 cells, when T2 cells infected with RCAS-HOXB13 (T2-HOXB13) were injected into nude mice, the resulting tumors were of comparable size to those generated with uninfected T2 cells and T2 cells infected with RCAS-GFP (T2-GFP). The same results were obtained with an independently derived cell line, T22 ( Table 1 ), indicating that HOXB13 does not enhance tumor proliferation in mouse ovarian cancer cell lines that contain genetic alterations in p53, c-myc, and Akt.
Taken together, these data demonstrate that HOXB13 is capable of enhancing tumorigenesis in the context of genetic alterations in p53, c-myc, and K-ras, but not in the context of genetic alterations in p53, c-myc, and Akt, suggesting that HOXB13 may collaborate with K-ras. To investigate the potential collaborative interaction of HOXB13 with ras, we stably transfected T22 cells with an empty pBabe vector (T22ϩvector), pBabe containing K-ras (T22ϩK-ras), or pBabe containing H-ras (T22ϩH-ras). These cell lines were then infected with RCAS-GFP or RCAS-HOXB13. Unlike T22 and T22ϩvector cells, which resulted in the same rate of growth whether they were infected with RCAS-GFP or RCAS-HOXB13 (Fig. 3 E and F) , the T22ϩK-ras and T22ϩH-ras cells resulted in significantly accelerated tumor growth when infected with RCAS-HOXB13 in comparison with identical cells infected with RCAS-GFP ( Fig.  3 G and H) .
Herein, we have demonstrated through ectopic expression and RNAi-mediated inhibition experiments that HOXB13 is a proproliferative modulator of ovarian cancer cell growth. Thus far, studies pertaining to the growth modulatory role of HOXB13 in human tumors have been limited to prostate and renal cell carcinoma cell lines. Interestingly, the results of these studies, in contrast to our findings, suggest that HOXB13 plays a tumor suppressor role in the kidney and prostate (14, 18, 19) . These contradictory findings are not necessarily surprising, because it is well known that the activity of HOX proteins depends on the cell in which the protein is acting (20) . A significant difference between ovary and organs such as prostate and kidney is that HOXB13 is absent in the normal ovary, whereas it is expressed at high levels in the normal prostate and kidney (14, 18, 19, 21) , where it is thought to play a role in epithelial cell differentiation (21, 22) . The HOXB13 expression pattern is reversed in cancers derived from these organs; HOXB13 is up-regulated in ovarian cancers (12) and down-regulated in renal and prostate carcinoma cell lines (14, 18, 19) . Thus, it is likely that tissue-and cell-specific contextual elements, such as endocrine target organspecific coactivators and corepressors, may play a vital role in dictating HOXB13 function.
HOXB13 Abrogates the Antagonistic Effect of Tamoxifen.
It is known that HOX genes are tightly regulated by hormones during development and in adult reproductive tissues (reviewed in ref. 23) . Interest in the functional role of HOXB13 in tumorigenesis originated from our previous observation that HOXB13 is overexpressed in tamoxifen-resistant human breast cancers. We recently demonstrated that HOXB13 expression is repressed by estradiol and that this repression is abrogated in the presence of tamoxifen (24) . These findings suggest a possible functional link between HOXB13 and tamoxifen resistance (i.e., aggressive tumor growth manifested as shortened disease-free survival). T1-GFP and T1-HOXB13 cells express estrogen receptor-␣ (ER) (Fig. 4A) , and in vitro exposure of these cells to estrogen results in increased proliferation, indicating that these cells possess a functional ER (Fig. 4B) . To determine whether HOXB13 is capable of modulating ER transcriptional activity, we evaluated whether ectopically expressed HOXB13 could modulate the ability of endogenously expressed ER to activate a promoter containing estrogen response element (ERE) sequences. Introduction of HOXB13 into T1 mouse ovarian cancer cell line results in enhanced estrogen-dependent ERE-luciferase expression (Fig. 4C) . To ascertain whether the HOXB13-enhanced transcriptional activation depends on ER, we performed ERE-transcriptional reporter assays in cells in which ER expression was knocked down with Faslodex, a drug that selectively accelerates ER degradation (25) . The knockdown of ER protein expression in T1-HOXB13 (Fig. 4C ) cells abrogates HOXB13-enhanced transcriptional activation supporting the notion that HOXB13-mediated ERE promoter activity is ER dependent. To determine the possible role of HOXB13 in tamoxifen resistance, we measured and compared tamoxifenmediated inhibition of ERE-transcriptional activity and tamoxifen-induced apoptosis in T1 cells expressing or lacking the expression of HOXB13. As expected, tamoxifen inhibits EREtranscriptional activation and induces apoptosis in T1-GFP cells. However, T1 cells expressing HOXB13 are resistant to the inhibitory effects of tamoxifen on ERE-mediated transcriptional activation (Fig. 4D) . Furthermore, HOXB13-expressing T1 cells are less sensitive to tamoxifen-induced apoptosis (Fig. 4E) . Taken together, our results indicate that HOXB13 has a pro-proliferative and pro-survival function in ovarian cancer cells and that HOXB13 may play an important role in the development of tamoxifen resistance in patients with ERpositive ovarian cancer. Although the majority of primary ovarian tumors express ERs (26) , the efficacy of endocrine therapies has not been adequately evaluated in ovarian cancer. Clinical studies of tamoxifen in a small number of chemoresistant ovarian cancer patients have demonstrated that a small subset of unselected patients responds to tamoxifen treatment (26) (27) (28) . However, a recent study has demonstrated that preselection of ovarian cancer patients according to ER status results in a significantly higher percentage of patients responding to antihormonal therapy (29) . This observation is analogous to that of human breast cancer in which there is an endocrine-sensitive subgroup among ER-positive ovarian cancers. In view of the observation that HOXB13 is expressed in a subset of human ovarian cancers and that HOXB13 is associated with tamoxifen resistance, it is possible that HOXB13 may serve not only as a biomarker but also as a functional regulator of antihormonal resistance in human ovarian cancer. Our observations and the recent resurgence of interest in endocrine therapies for ovarian cancer (29) merit further investigation of these hypotheses at the clinical and basic science levels. 
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